(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with ...

According to the Adhishthana framework, stocks typically form a Cakra structure between Phases 4-8, a channel-like setup with an arc that generally carries bullish implications. Once a stock breaks ...

Credit: Getty Images. Tradipitant is a neurokinin-1 receptor antagonist. Tradipitant was found to be superior to placebo in preventing vomiting associated with motion sickness, according to results ...

“We think so much of our Phase III Supercars that we guarantee they will turn at least 120 mph in 11.50 seconds or better with an approved driver on an AHRA or NHRA-sanctioned drag strip.” That was ...

WASHINGTON, May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its Phase III study of tradipitant in motion sickness, confirming the ...

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. Background: Tenosynovial giant cell tumor (TGCT) ...

Health Canada’s approval enables 4Moving Biotech to initiate the INFLAM MOTION Phase 2a clinical trial The INFLAM MOTION trial serves as a proof-of-concept study for 4Moving Biotech’s flagship 4P004 ...